Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus tiragolumab versus atezolizumab plus placebo in first-line PD-L1-positive recurrent or metastatic head and neck squamous cell carcinoma
2020-002852-19Phase 2Active
- Sponsor
- Roche
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing Atezolizumab plus tiragolumab with Atezolizumab plus placebo (2 arms). Primary endpoint: Confirmed objective response rate. Started Nov 2020; status: active.
02
Drugs
tiragolumabatezolizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2020-002852-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002852-19.